Preview

FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology

Advanced search

Long-term analysis of сanagliflozin budget impact in adult patients with type 2 diabetes mellitus and diabetic nephropathy in the Russian Federation

https://doi.org/10.17749/2070-4909/farmakoekonomika.2022.150

Abstract

Background. Diabetic nephropathy (DN) is a specific kidney lesion in patients with diabetes mellitus, which leads to the development of endstage kidney disease and requires substitutive renal therapy (dialysis or transplantation). Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor, which exerts a renoprotective effect. According to the published data, the application of canagliflozin in patients with type 2 diabetes mellitus (DM2) and DN could postpone dialysis therapy for almost 13 years.

Objective: to perform a long-term analysis of canagliflozin budget impact in adult patients with DM2 and DN from the point of view of the constituent entities of the Russian Federation.

Material and methods. A group of comparison for canagliflozin was placebo (no renoprotective pharmacotherapy). The authors proposed a mathematical model for DN progression in groups of patients who received canagliflozin (100 mg orally, daily, long-term) or placebo. The model was based on the extrapolation of the CREDENCE study data. The model was used for the analysis of the direct costs on the lifetime pharmacotherapy and dialysis per one patient. Epidemiologic data from the federal register on the number of adult patients with DM and DN prevalence among these patients were used to evaluate the size of the target population. Based on the clinical recommendations and the medical care standards for patients with DM and the data on the actual state procurement of SGLT2 inhibitors and glucagon-like peptide-1 receptor agonists in 2021, we evaluated the share of patients with DM2+DN who currently do not receive renoprotective therapy but who must be supplied with canagliflozin according to the standards. Among this population, we determined the patients with the glomerular filtration rate within 30–90 ml/min/1.73 m2, which provides the comparability of the target population with patients included in CREDENCE clinical study.

Results. Direct medical costs per one patient receiving canagliflozin therapy were 678 108 rubles, which was 52.8% (759,239 rubles) lower than without renoprotective pharmacotherapy (1,437,347 rubles). As a result, considering the modeling period and current practice, the budget costs for pharmacotherapy of patients with DM2+DN were 99.82 billion rubles, in comparison with the proposed practice, which was 47.09 billion rubles (difference in budget costs is 52.73 billion rubles, or 52.8%). The accumulated costs of the regional health care system were lower in patients receiving canagliflozin in comparison with patients without renoprotective pharmacotherapy 11 years after the beginning of treatment.

Conclusion. The expansion of canagliflozin application in the therapy for patients with DM2+DN leads to the budget cost cuts in the long run due to the extension of the dialysis-free period.

About the Authors

N. A. Avxentyev
Financial Research Institute; Institute for Applied Economic Research, Russian Presidential Academy of National Economy and Public Administration
Russian Federation

Nikolay N. Avxentyev – Advisоr, Financial Research Institute; Researcher, Institute for Applied Economic Research, Russian Presidential Academy of National Economy and PA. RSCI SPIN-code: 8649-2773.

3/2 Nastasyinskiy Aly, Moscow 127006; 84 bldg 1, Vernadskiy Ave., Moscow 119571



Yu. V. Makarova
Financial Research Institute
Russian Federation

Yulia V. Makarova – PhD (Econ.), Senior Researcher; RSCI SPINcode: 9826-4864.

3/2 Nastasyinskiy Aly, Moscow 127006



References

1. Clinical Guidelines Rubricator. Type 2 diabetes mellitus in adults. Available at: http://sd.diaregistry.ru (in Russ.) (accessed 24.01.2022).

2. Federal Register of Patients with Diabetes Mellitus. Available at: http://sd.diaregistry.ru (in Russ.) (accessed 10.02.2022).

3. Shamkhalova M.S., Vikulova O.K., Zheleznyakova A.V., et al. Trends in the epidemiology of chronic kidney disease in Russian Federation according to the Federal Diabetes Register (2013–2016). Diabetes Mellitus. 2018; 21 (3): 160–9 (in Russ.). https://doi.org/10.14341/DM9687.

4. Klochkova E.V., Tolmacheva A.A., Chernova N.N., Nikolskaya I.N. Diabetic nephropathy and chronic kidney disease in type 2 diabetes. Siberian Medical Review. 2019; 5: 29–37 (in Russ.). https://doi.org/10.20333/2500136-2019-5-29-32.

5. Instructions for the use of the drug Invokana®. Available at: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=7e19c450-bd8a4fa4-a9f1-f789b8515544&t= (in Russ.) (accessed 10.02.2022).

6. Shestakova M.V., Ametov A.S., Antsiferov M.B., et al. Canagliflozin: from glycemic control to improvement of cardiovascular and renal prognosis in patients with type 2 diabetes mellitus. Resolution of Advisory Board. Diabetes Mellitus. 2021; 24 (5): 479–86 (in Russ.). https://doi.org/10.14341/DM12848.

7. Perkovic V., Jardine M.J., Neal B., et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. New Engl J Med. 2019; 380 (24): 2295–306. https://doi.org/10.1056/NEJMoa1811744.

8. Durkin M., Blais J. Linear projection of estimated glomerular filtration rate decline with canagliflozin and implications for dialysis utilization and cost in diabetic nephropathy. Diabetes Ther. 2021; 12 (2): 499–508. https://doi.org/10.1007/s13300-020-00953-4.

9. Clinical guidelines “Treatment of patients with stage 5 chronic kidney disease (CKD 5) by hemodialysis and hemodiafiltration”. Available at: http://www.nephro.ru/content/files/recomendations/GuidelinesHdNational.pdf (in Russ.) (accessed 15.07.2022).

10. Omelyanovskiy V.V., Avxentyeva M.V., Khachatryan G.R. Methodological recommendations on the use of mathematical modeling in clinical and economic research and research using budget impact analysis. Мoscow; 2019: 59 pp. (in Russ.).

11. Methodological recommendations on ways to pay for medical care at the expense of Compulsory Health Insurance. Available at: https://www.garant.ru/products/ipo/prime/doc/403402448/ (in Russ.) (accessed 15.07.2022).

12. Decree of the Government of the RF of 28.12.2021 No. 2505 “On the Program of state guarantees of free medical care for citizens for 2022 and for the planning period of 2023 and 2024”. Available at: https://base.garant.ru/403335795/ (in Russ.) (accessed 15.07.2022).

13. Order of the Ministry of Health of the RF of 01.10.2020 No. 1054n “On approval of standards of medical care for adults with type 2 diabetes mellitus”. Available at: https://base.garant.ru/400297064/ (in Russ.) (accessed 15.07.2022).


Review

For citations:


Avxentyev N.A., Makarova Yu.V. Long-term analysis of сanagliflozin budget impact in adult patients with type 2 diabetes mellitus and diabetic nephropathy in the Russian Federation. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2022;15(3):309-318. (In Russ.) https://doi.org/10.17749/2070-4909/farmakoekonomika.2022.150

Views: 650


ISSN 2070-4909 (Print)
ISSN 2070-4933 (Online)